August 2025 brought significant advances in therapies for conditions ranging from metabolic liver disease to pediatric migraine prevention and beyond. Tune in as we delve into key FDA approvals like Novo Nordisk's Wegovy for MASH, Tonmya for fibromyalgia, and Ajovy's pediatric migraine approval, and explore their implications in clinical practice.

• Wegovy (semaglutide) for metabolic liver disease: Now indicated for metabolic dysfunction-associated steatohepatitis (MASH) in adults, offering a new treatment pathway for this progressive liver condition.
• Tonmya (cyclobenzaprine) for fibromyalgia: A potent sublingual treatment, provides hope in managing fibromyalgia's chronic pain and sleep disturbances.
• Ajovy (fremanezumab) for pediatric migraines: The first anti-CGRP therapy approved for migraine prevention in children, opening new avenues for managing this debilitating condition.
• Repatha (evolocumab) for cardiovascular risk: Expanded use in adults at risk for major cardiovascular events, even absent diagnosed cardiovascular disease.
• Brinsupri (brensocatib) for bronchiectasis: Provides a novel oral option for reducing flares in non-cystic fibrosis bronchiectasis, promising symptom relief.

Chapters:

• (00:00) - Intro
• (00:41) - Wegovy
• (01:41) - Tonmya
• (02:32) - Ajovy
• (03:19) - Repatha
• (03:57) - Brinsupri
• (04:26) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app